Randomized Trial Demonstrating No Translocation of Intact Intestinal Bacteria During Hemodialysis or Hemodiafiltration

Introduction: The low incidence of intradialytic hypotension (IDH) in high-volume (HV) hemodiafiltration (HDF) may help in maintaining gut perfusion during treatment. Preservation of gut endothelial integrity would limit or prevent bacterial translocation and subsequent systemic inflammation, which...

Full description

Saved in:
Bibliographic Details
Main Authors: Paul A. Rootjes, Muriel P.C. Grooteman, Andries E. Budding, Hetty J. Bontkes, Gertrude Wijngaarden, Menso J. Nubé, Camiel L.M. de Roij van Zuijdewijn
Format: Article
Language:English
Published: Elsevier 2025-01-01
Series:Kidney International Reports
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S2468024924019557
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850223562098475008
author Paul A. Rootjes
Muriel P.C. Grooteman
Andries E. Budding
Hetty J. Bontkes
Gertrude Wijngaarden
Menso J. Nubé
Camiel L.M. de Roij van Zuijdewijn
author_facet Paul A. Rootjes
Muriel P.C. Grooteman
Andries E. Budding
Hetty J. Bontkes
Gertrude Wijngaarden
Menso J. Nubé
Camiel L.M. de Roij van Zuijdewijn
author_sort Paul A. Rootjes
collection DOAJ
description Introduction: The low incidence of intradialytic hypotension (IDH) in high-volume (HV) hemodiafiltration (HDF) may help in maintaining gut perfusion during treatment. Preservation of gut endothelial integrity would limit or prevent bacterial translocation and subsequent systemic inflammation, which may contribute to the low mortality rate in HV-HDF. Methods: Forty patients were cross-over randomized to standard (hemodialysis [HD]) (S-HD), cool HD (C-HD), and HDF (low-volume [LV] and HV, convection volume (CV) of 15 L and ≥ 23 L per session, respectively), each for 2 weeks. Quantitative assessment of microbial DNA (mDNA) in blood was performed before and after dialysis by 16S to 23S interspace profiling after DNA isolation. The intradialytic acute phase response (APR) was evaluated by high-sensitivity C-reactive protein (hs-CRP), interleukin-6 receptor (IL-6R), soluble CD14 (sCD14), and vascular-cell-adhesion molecule-1 (VCAM-1). Differences between modalities were primary objectives. Results: mDNA was absent from all samples. IL-6R, sCD14, and VCAM-1 increased equally in all modalities (median increase: 12.5%, 14.0%, 14.8%, respectively; P < 0.05). hs-CRP increased only in C-HD and HV-HDF (median increase: 12.6%, P < 0.05). After correction for hemoconcentration, most APR markers decreased (median: sCD14, −11.3% and VCAM-1, −14.4% in all modalities; IL-6R, −13.4% in C-HD, LV-HDF, and HV-HDF; P < 0.05). hs-CRP only decreased in C-HD (−13.5%, P = 0.004). Conclusion: From this study, we conclude as follows: (i) circulating mDNA could not be demonstrated; (ii) in the crude analysis, a similar APR was noted in all modalities, individual markers remained stable or declined after correction for hemoconcentration; and (iii) because neither bacterial translocation nor an APR was observed in either modality, it is highly unlikely that the superior survival of HV-HDF is explained by a superior preservation of gut integrity.
format Article
id doaj-art-c69d255ab0da4306a87d7941e0745914
institution OA Journals
issn 2468-0249
language English
publishDate 2025-01-01
publisher Elsevier
record_format Article
series Kidney International Reports
spelling doaj-art-c69d255ab0da4306a87d7941e07459142025-08-20T02:05:52ZengElsevierKidney International Reports2468-02492025-01-0110110911910.1016/j.ekir.2024.09.025Randomized Trial Demonstrating No Translocation of Intact Intestinal Bacteria During Hemodialysis or HemodiafiltrationPaul A. Rootjes0Muriel P.C. Grooteman1Andries E. Budding2Hetty J. Bontkes3Gertrude Wijngaarden4Menso J. Nubé5Camiel L.M. de Roij van Zuijdewijn6Amsterdam UMC, location AMC, Nephrology, Amsterdam, the Netherlands; Amsterdam Cardiovascular Sciences (ACS), Diabetes and Metabolism, Amsterdam, the Netherlands; Department of Internal Medicine, Gelre Hospitals, location Apeldoorn, Apeldoorn, the NetherlandsAmsterdam UMC, location AMC, Nephrology, Amsterdam, the Netherlands; Amsterdam Cardiovascular Sciences (ACS), Diabetes and Metabolism, Amsterdam, the NetherlandsInBiome, Amsterdam, the NetherlandsDepartment of Clinical Chemistry, Medical Immunology Laboratory and Amsterdam Infection and Immunity, Amsterdam UMC, Amsterdam, the NetherlandsAmsterdam UMC, location AMC, Nephrology, Amsterdam, the Netherlands; Amsterdam Cardiovascular Sciences (ACS), Diabetes and Metabolism, Amsterdam, the NetherlandsAmsterdam UMC, location AMC, Nephrology, Amsterdam, the Netherlands; Amsterdam Cardiovascular Sciences (ACS), Diabetes and Metabolism, Amsterdam, the NetherlandsAmsterdam UMC, location AMC, Nephrology, Amsterdam, the Netherlands; Amsterdam Cardiovascular Sciences (ACS), Diabetes and Metabolism, Amsterdam, the Netherlands; Department of Internal Medicine, Spaarne Gasthuis, Haarlem, the Netherlands; Correspondence: Camiel L. M. de Roij van Zuijdewijn, Amsterdam UMC, location AMC, Nephrology Meibergdreef 9, 1105 AZ, Amsterdam, the Netherlands.Introduction: The low incidence of intradialytic hypotension (IDH) in high-volume (HV) hemodiafiltration (HDF) may help in maintaining gut perfusion during treatment. Preservation of gut endothelial integrity would limit or prevent bacterial translocation and subsequent systemic inflammation, which may contribute to the low mortality rate in HV-HDF. Methods: Forty patients were cross-over randomized to standard (hemodialysis [HD]) (S-HD), cool HD (C-HD), and HDF (low-volume [LV] and HV, convection volume (CV) of 15 L and ≥ 23 L per session, respectively), each for 2 weeks. Quantitative assessment of microbial DNA (mDNA) in blood was performed before and after dialysis by 16S to 23S interspace profiling after DNA isolation. The intradialytic acute phase response (APR) was evaluated by high-sensitivity C-reactive protein (hs-CRP), interleukin-6 receptor (IL-6R), soluble CD14 (sCD14), and vascular-cell-adhesion molecule-1 (VCAM-1). Differences between modalities were primary objectives. Results: mDNA was absent from all samples. IL-6R, sCD14, and VCAM-1 increased equally in all modalities (median increase: 12.5%, 14.0%, 14.8%, respectively; P < 0.05). hs-CRP increased only in C-HD and HV-HDF (median increase: 12.6%, P < 0.05). After correction for hemoconcentration, most APR markers decreased (median: sCD14, −11.3% and VCAM-1, −14.4% in all modalities; IL-6R, −13.4% in C-HD, LV-HDF, and HV-HDF; P < 0.05). hs-CRP only decreased in C-HD (−13.5%, P = 0.004). Conclusion: From this study, we conclude as follows: (i) circulating mDNA could not be demonstrated; (ii) in the crude analysis, a similar APR was noted in all modalities, individual markers remained stable or declined after correction for hemoconcentration; and (iii) because neither bacterial translocation nor an APR was observed in either modality, it is highly unlikely that the superior survival of HV-HDF is explained by a superior preservation of gut integrity.http://www.sciencedirect.com/science/article/pii/S2468024924019557hemodiafiltrationhemodialysisbacterial DNAintestinal translocationacute phase response (APR)randomized cross-over trial
spellingShingle Paul A. Rootjes
Muriel P.C. Grooteman
Andries E. Budding
Hetty J. Bontkes
Gertrude Wijngaarden
Menso J. Nubé
Camiel L.M. de Roij van Zuijdewijn
Randomized Trial Demonstrating No Translocation of Intact Intestinal Bacteria During Hemodialysis or Hemodiafiltration
Kidney International Reports
hemodiafiltration
hemodialysis
bacterial DNA
intestinal translocation
acute phase response (APR)
randomized cross-over trial
title Randomized Trial Demonstrating No Translocation of Intact Intestinal Bacteria During Hemodialysis or Hemodiafiltration
title_full Randomized Trial Demonstrating No Translocation of Intact Intestinal Bacteria During Hemodialysis or Hemodiafiltration
title_fullStr Randomized Trial Demonstrating No Translocation of Intact Intestinal Bacteria During Hemodialysis or Hemodiafiltration
title_full_unstemmed Randomized Trial Demonstrating No Translocation of Intact Intestinal Bacteria During Hemodialysis or Hemodiafiltration
title_short Randomized Trial Demonstrating No Translocation of Intact Intestinal Bacteria During Hemodialysis or Hemodiafiltration
title_sort randomized trial demonstrating no translocation of intact intestinal bacteria during hemodialysis or hemodiafiltration
topic hemodiafiltration
hemodialysis
bacterial DNA
intestinal translocation
acute phase response (APR)
randomized cross-over trial
url http://www.sciencedirect.com/science/article/pii/S2468024924019557
work_keys_str_mv AT paularootjes randomizedtrialdemonstratingnotranslocationofintactintestinalbacteriaduringhemodialysisorhemodiafiltration
AT murielpcgrooteman randomizedtrialdemonstratingnotranslocationofintactintestinalbacteriaduringhemodialysisorhemodiafiltration
AT andriesebudding randomizedtrialdemonstratingnotranslocationofintactintestinalbacteriaduringhemodialysisorhemodiafiltration
AT hettyjbontkes randomizedtrialdemonstratingnotranslocationofintactintestinalbacteriaduringhemodialysisorhemodiafiltration
AT gertrudewijngaarden randomizedtrialdemonstratingnotranslocationofintactintestinalbacteriaduringhemodialysisorhemodiafiltration
AT mensojnube randomizedtrialdemonstratingnotranslocationofintactintestinalbacteriaduringhemodialysisorhemodiafiltration
AT camiellmderoijvanzuijdewijn randomizedtrialdemonstratingnotranslocationofintactintestinalbacteriaduringhemodialysisorhemodiafiltration